Suppr超能文献

干细胞在视网膜修复中的应用现状

Current focus of stem cell application in retinal repair.

作者信息

Alonso-Alonso María L, Srivastava Girish K

机构信息

María L Alonso-Alonso, Girish K Srivastava, Instituto Universitario de Obtalmobiología Aplicada (IOBA), Universidad de Valladolid, 47011 Valladolid, Spain.

出版信息

World J Stem Cells. 2015 Apr 26;7(3):641-8. doi: 10.4252/wjsc.v7.i3.641.

Abstract

The relevance of retinal diseases, both in society's economy and in the quality of people's life who suffer with them, has made stem cell therapy an interesting topic for research. Embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adipose derived mesenchymal stem cells (ADMSCs) are the focus in current endeavors as a source of different retinal cells, such as photoreceptors and retinal pigment epithelial cells. The aim is to apply them for cell replacement as an option for treating retinal diseases which so far are untreatable in their advanced stage. ESCs, despite the great potential for differentiation, have the dangerous risk of teratoma formation as well as ethical issues, which must be resolved before starting a clinical trial. iPSCs, like ESCs, are able to differentiate in to several types of retinal cells. However, the process to get them for personalized cell therapy has a high cost in terms of time and money. Researchers are working to resolve this since iPSCs seem to be a realistic option for treating retinal diseases. ADMSCs have the advantage that the procedures to obtain them are easier. Despite advancements in stem cell application, there are still several challenges that need to be overcome before transferring the research results to clinical application. This paper reviews recent research achievements of the applications of these three types of stem cells as well as clinical trials currently based on them.

摘要

视网膜疾病在社会经济以及患者生活质量方面都具有重要意义,这使得干细胞疗法成为一个备受关注的研究课题。胚胎干细胞(ESCs)、诱导多能干细胞(iPSCs)和脂肪来源间充质干细胞(ADMSCs)是目前研究的重点,有望成为不同视网膜细胞(如光感受器和视网膜色素上皮细胞)的来源。其目的是将这些细胞用于细胞替代疗法,以治疗目前处于晚期仍无法治愈的视网膜疾病。尽管胚胎干细胞具有巨大的分化潜力,但存在形成畸胎瘤的风险以及伦理问题,在开展临床试验之前必须解决这些问题。诱导多能干细胞与胚胎干细胞一样,能够分化为多种类型的视网膜细胞。然而,获取用于个性化细胞治疗的诱导多能干细胞在时间和金钱方面成本高昂。由于诱导多能干细胞似乎是治疗视网膜疾病的一个现实选择,研究人员正在努力解决这一问题。脂肪来源间充质干细胞的优势在于获取过程较为简便。尽管干细胞应用取得了进展,但在将研究成果转化为临床应用之前,仍有几个挑战需要克服。本文综述了这三种类型干细胞应用的最新研究成果以及目前基于它们开展的临床试验。

相似文献

1
Current focus of stem cell application in retinal repair.干细胞在视网膜修复中的应用现状
World J Stem Cells. 2015 Apr 26;7(3):641-8. doi: 10.4252/wjsc.v7.i3.641.
2
Stem Cell Therapies in Retinal Disorders.视网膜疾病的干细胞疗法
Cells. 2017 Feb 2;6(1):4. doi: 10.3390/cells6010004.
3
Stem cell treatment of degenerative eye disease.干细胞治疗退行性眼病。
Stem Cell Res. 2015 May;14(3):243-57. doi: 10.1016/j.scr.2015.02.003. Epub 2015 Feb 24.
7
Strategies for retinal cell generation from human pluripotent stem cells.从人多能干细胞生成视网膜细胞的策略。
Stem Cell Investig. 2017 Jul 25;4:65. doi: 10.21037/sci.2017.07.02. eCollection 2017.
10
How far are induced pluripotent stem cells from the clinic?诱导多能干细胞离临床应用还有多远?
Ageing Res Rev. 2010 Jul;9(3):257-64. doi: 10.1016/j.arr.2010.03.001. Epub 2010 Apr 1.

引用本文的文献

3
The Rise of Retinal Organoids for Vision Research.视网膜类器官在视觉研究中的崛起。
Int J Mol Sci. 2020 Nov 11;21(22):8484. doi: 10.3390/ijms21228484.
10
The promise of stem cell-based therapeutics in ophthalmology.眼科中基于干细胞疗法的前景。
Neural Regen Res. 2017 Feb;12(2):173-180. doi: 10.4103/1673-5374.200793.

本文引用的文献

4
Mesenchymal stem cells: new players in retinopathy therapy.间充质干细胞:视网膜病变治疗中的新角色。
Front Endocrinol (Lausanne). 2014 Apr 24;5:59. doi: 10.3389/fendo.2014.00059. eCollection 2014.
10
Retinal repair with induced pluripotent stem cells.诱导多能干细胞的视网膜修复。
Transl Res. 2014 Apr;163(4):377-86. doi: 10.1016/j.trsl.2013.11.002. Epub 2013 Nov 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验